TD Cowen Maintains Buy on Medtronic, Raises Price Target to $110
TD Cowen analyst Joshua Jennings maintains Medtronic (NYSE:MDT) with a Buy and raises the price target from $100 to $110.
Read original at benzingaStocks · News reference
Medtronic Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Medtronic plc (NYSE: MDT) will release Q1 earnings on Sept. 1. Analysts predict $1.39 EPS and $9.54B revenue. Stock fell 2.2% to $89.97 on Aug. 27.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 28, 2026, 10:03 AM
- Checked
- Aug 28, 2026, 10:03 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Needham Maintains Buy on Medtronic, Raises Price Target to $114
Needham analyst Mike Matson maintains Medtronic (NYSE:MDT) with a Buy and raises the price target from $101 to $114.
Read original at benzingaAtrial Fibrillation Treatment Devices Market Trends and Forecast, 2035 | Includes Profiles of Abbott, AtriCure, Boston Scientific, Johnson & Johnson, and Medtronic
The global atrial fibrillation treatment devices market is expected to grow at a 13.1% CAGR from $9.6 billion in 2026 to $29 billion by 2035, driven by aging populations, rising AF prevalence affecting 50-60 million people worldwide, and increasing adoption of advanced ablation and left atrial appendage closure technologies. Pulsed field ablation is forecast to generate over 60% of market revenue by 2035, while North America will retain approximately 50% of global market share. Asia-Pacific is expected to register the fastest regional growth.
Read original at globenewswire-inc